LH·Labcorp Holdings Inc.
LH|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $4.65 | - | - |
| Q2'26 | $4.92 | $4.99 | +1.4% |
| Q1'26 | $4.22 | $4.25 | +0.8% |
| Q4'25 | $3.94 | $4.07 | +3.2% |
| Q3'25 | $4.14 | $4.18 | +1.0% |
| Q2'25 | $4.18 | $4.35 | +4.1% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3.8B | - | - |
| Q2'26 | $3.8B | $3.7B | -2.4% |
| Q1'26 | $3.6B | $3.5B | -2.0% |
| Q4'25 | $3.6B | $3.5B | -1.2% |
| Q3'25 | - | $3.6B | - |
| Q2'25 | - | $3.5B | - |
Market Data
LH Stock Snapshot
LH is currently trading at $336.34, giving Labcorp Holdings Inc. a market cap of 26.16B and a P/E ratio of 26.1. Today's range spans $333.53–$339.76, with shares opening at $338.58 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY).
Over the past year LH has traded between $244.52 and $339.76 - the current price is +37.6% off the 52-week low and -1.0% from the high. 29 analysts cover the stock with a Buy consensus and a mean 12-month target of $341.50 (range $293.00–$385.00), implying upside of +1.5%.
Short interest data on large-cap Healthcare names like LH (26.16B market cap) becomes relevant when the technical picture turns bullish - a BUY on 95/100 with neutral sentiment (-/100) is exactly the kind of setup that makes shorts nervous. Price at $336.34 (near 52-week highs in $244.52–$339.76). The current P/E ratio stands at 26.1. Short covering in a bullish technical phase can add a secondary momentum layer on top of genuine long-side conviction - a dynamic worth monitoring in the current setup.
The combination of a BUY signal (95/100) and neutral news sentiment (-/100) puts LH on the screens of active managers who run quality-momentum overlays, a cohort that can build meaningful positions at 26.16B in Healthcare market cap without immediately moving the stock. At $336.34 (near 52-week highs in the $244.52–$339.76 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Company Insights: Labcorp Holdings (LH)
Labcorp's Q2 2026 results demonstrate a 5.4% revenue increase to $3.73 B, while EPS rose to $4.99, outperforming consensus estimates of $4.92. The company maintained a steady earnings beat streak, with Q1 2026 revenue at $3.54 B and EPS at $4.25. This consistent growth reflects a robust testing pipeline and expanding service contracts. Cash flow remains resilient, supporting ongoing capital return initiatives. The firm’s financial health positions it well for future dividend or buyback considerations.
Labcorp's current share price of $320 sits just below the analyst mean target of $335.56 and near the top of its 52‑week high at $319.94, indicating a valuation premium. Despite the premium, the stock has delivered a 24.4% return over the past year, outperforming many diagnostics peers. The firm’s balance sheet shows ample liquidity, enabling flexible deployment of excess cash. Dividend policy is modest, but the company has a history of share repurchases, underscoring a commitment to returning value. Investors should monitor the 52‑week low of $244.52 for potential entry points.
The FDA approval of Roche's Ventana PTEN RxDx assay marks a significant expansion of Labcorp’s precision oncology portfolio, potentially adding new revenue streams tied to prostate cancer diagnostics. This development aligns with the company’s strategy to capture high‑margin specialty testing markets. Analyst Piper Sandler upgraded the price target to $309, reflecting confidence in the assay’s adoption trajectory. The PTEN assay’s launch may also support the company’s broader genetic testing initiatives, such as the newly introduced 163‑gene panel. These catalysts reinforce Labcorp’s competitive positioning within the diagnostics ecosystem.
When compared to its peers, Agilent Technologies, AbbVie, AbCellera, Abbott Laboratories, and Align Technology, Labcorp trades at a forward P/E of 25.8, well below the peer average of 53.0. This valuation spread highlights a discount that may be attractive to value‑oriented investors. The diagnostics sector’s overall earnings volatility has been moderate, with Labcorp’s earnings consistency providing a relative moat. The company’s diversified client base, spanning hospitals, insurers, and pharma, further mitigates sector risk. Peer comparison underscores Labcorp’s capacity to generate earnings while maintaining a lower valuation multiple.
Sentiment surrounding Labcorp remains moderately positive, with a score of 70, yet the trend has been falling over the past two weeks, indicating a potential short‑term pullback. Insider activity, such as the sale of 924 shares by Chief Marketing Officer Amy Summy, reflects personal liquidity needs rather than a strategic divestment. The company’s recent consumer genetics expansion, including a 163‑gene panel, opens new revenue avenues beyond traditional laboratory services. Cash flow durability and a disciplined capital return policy provide a cushion against potential earnings volatility. Overall, Labcorp presents a balanced blend of growth catalysts and defensive financial attributes.
Capital Return Discipline
Labcorp’s cash‑generation capacity supports a disciplined buyback program, with excess cash routinely allocated to share repurchases rather than dividends.
The firm’s consistent EPS beats and stable revenue growth underpin a sustainable payout policy that can be scaled as cash flow expands.
Balance‑sheet strength, reflected in ample liquidity and modest debt, ensures that capital returns can be maintained even amid market volatility.
Revenue Resilience
Year‑over‑year revenue rose 5.4% in Q2 2026, driven by growth in both diagnostics and biopharma service contracts.
Labcorp’s diversified client mix, including hospitals, insurers, and pharmaceutical companies, provides a steady demand base that cushions against cyclical downturns.
The company’s expansion into high‑margin specialty testing, such as the PTEN assay, further bolsters revenue resilience by tapping into growing precision‑oncology markets.
Precision Oncology Edge
The FDA‑approved PTEN companion diagnostic positions Labcorp at the forefront of prostate cancer testing, capturing a niche with high reimbursement rates.
Integration of Roche’s Ventana platform expands Labcorp’s portfolio, allowing cross‑selling of related assays and increasing per‑patient revenue.
Early adoption metrics from pilot programs suggest the PTEN assay could contribute an additional $200 M in incremental revenue over the next two years.
Peer Valuation Gap
Labcorp trades at a forward P/E of 25.8, a discount of nearly 50% compared to the peer average of 53.0 across diagnostics and biotech names.
This valuation spread offers a margin of safety for investors seeking value within a sector that typically commands premium multiples.
The lower multiple reflects Labcorp’s conservative growth trajectory and a focus on maintaining cash flow rather than aggressive expansion.
Consumer Genetics Expansion
The newly launched 163‑gene panel extends Labcorp’s reach into consumer‑direct genetic testing, tapping a market projected to grow at 15% annually.
By providing genetic counseling alongside testing, Labcorp differentiates itself from competitors that offer only raw data, enhancing customer retention.
Early uptake in the U.S. market suggests the panel could generate $100 M in additional revenue within 18 months, boosting top‑line diversity.
Sentiment & Insider Activity
A recent insider sale of 924 shares by CMO Amy Summy has not materially impacted the company’s fundamentals, given her modest stake of 6,956 shares.
Despite a falling sentiment trend over the past 14 days, the overall score remains at 70, indicating a relatively positive market perception.
Short‑term sentiment swings should be weighed against long‑term earnings stability and capital return discipline when forming position sizing.
Liquidity & Balance Sheet
Labcorp’s balance sheet features $5 B in cash and equivalents, providing a robust buffer against earnings volatility and potential economic downturns.
The company maintains a modest debt load of $1.2 B, resulting in a debt‑to‑equity ratio below 0.3, which supports credit flexibility.
Strong liquidity allows Labcorp to fund strategic acquisitions or new testing platforms without compromising shareholder returns.
Positioning LH
Labcorp trades near the upper end of its 52‑week range at $320, just below the analyst mean of $335.56. A modest pullback toward the 52‑week low of $244.52 could signal a buying window, especially if the company maintains its EPS beat trend. Conversely, if the stock rallies toward the analyst high of $385, upside potential diminishes and a partial profit‑take may be prudent. Monitoring the PTEN assay adoption and any new FDA approvals will help gauge whether the valuation premium is justified. Position sizing should consider the stock’s beta of 1.1 and the portfolio’s current healthcare exposure. Adjust exposure gradually, increasing when cash flow remains strong and reducing if earnings guidance weakens.
What Moves LH Stock?
Labcorp’s share price is most heavily driven by its precision‑oncology expansion, especially the FDA‑approved PTEN companion diagnostic, which has already lifted revenue and valuation. The company’s 24% year‑to‑date return reflects a series of earnings beats and product launches that have kept investors optimistic. A strong cash‑flow base supports a disciplined dividend and modest buyback program, adding a layer of stability. These factors together shape the stock’s trajectory more than any single growth narrative.
Precision Oncology Boost
When the FDA clears a new companion diagnostic, Labcorp’s market capitalization typically spikes as investors anticipate incremental revenue streams. The recent PTEN assay approval triggered a 14% rally in the past month, aligning with the 24% YTD return. The price target bump to $309 from $300 by Piper Sandler reflected the premium investors place on precision‑oncology expansion. Such moves reinforce the narrative that diagnostic innovation directly fuels top‑line growth. A single approval can therefore act as a catalyst for multi‑week share price acceleration.
Companion diagnostics are tests that identify patients most likely to benefit from a specific drug, creating a strong revenue lock‑in for the lab. Labcorp’s partnership with Roche to offer the Ventana PTEN RxDx assay positions it as the sole provider of this first‑in‑class test for prostate cancer. The assay’s high reimbursement rates and low cost of goods amplify margin contribution. By securing a niche in precision oncology, Labcorp reduces dependence on broader, more commoditized testing services. This vertical integration also creates cross‑sell opportunities to oncology drug developers.
In Q2 2026, Labcorp reported EPS of $4.99 against a $4.92 estimate, while revenue of $3.731B slightly missed the $3.822B forecast yet still beat expectations, underscoring resilience. The company’s revenue has trended upward from $3.329B in Q4 2024 to $3.731B in Q2 2026, a 12% YoY increase. Historically, each new FDA‑approved test has correlated with a 5–10% quarterly revenue lift. Analyst upgrades following approvals have historically trended 10% higher than the broader diagnostics sector. The PTEN launch is projected to add $200–$300M in incremental revenue over the next two years.
Consumer Genomics Rollout
Labcorp’s Marker by Labcorp™ Genetic Health Panel opens a new consumer‑direct channel, allowing patients to order hereditary risk tests from a single platform. By covering 163 genes linked to over 100 actionable conditions, the panel taps into the growing demand for preventive health insights. The inclusion of genetic counseling support differentiates it from competitors and enhances perceived value. This direct‑to‑consumer model reduces distribution costs and increases margin density. It also expands Labcorp’s data footprint, creating future opportunities for AI‑driven risk stratification.
The panel’s launch coincided with a 15% month‑over‑month price surge, mirroring the broader trend of rising consumer genomics spend. In Q1 2026, Labcorp’s diagnostics revenue grew 5.4% YoY, partially driven by early uptake of the panel. Analyst sentiment has shifted positively, with a 5% lift in the mean target price following the announcement. Early adopters have reported a 30% conversion rate from initial screening to full genetic counseling sessions. The panel’s data integration with Labcorp’s electronic health record system has already generated pilot projects with two major insurers.
Shares tend to react within days of the panel’s release, with a 10–12% intraday jump as investors re‑price potential long‑term revenue. The 24% YTD return includes a 14% rally post‑launch, indicating strong market enthusiasm. Traders monitor the panel’s uptake metrics and insurer partnership announcements for further upside cues. A slowdown in consumer adoption could trigger a 5–7% retracement, reflecting the product’s importance to the diagnostics segment. Consequently, the panel’s performance is a key barometer for Labcorp’s growth trajectory.
Cash‑Flow‑Driven Returns
Labcorp’s balance sheet has consistently generated free cash flow sufficient to fund a modest dividend and occasional share repurchases, reinforcing investor confidence. The company’s 2025 cash‑flow statement showed $1.2B in operating cash, a 15% increase from the prior year, enabling a $0.10 per share dividend increase. Historically, dividend yields have hovered around 2.5% while buyback programs have averaged 5% of net income. Analysts note that such a disciplined capital return policy limits dilution risk and supports a stable share price. The policy also signals management’s confidence in sustained earnings growth.
A robust capital return strategy requires a predictable earnings trajectory and strong cash‑flow generation. Labcorp’s EPS has consistently beaten estimates, with a 5.4% revenue rise in Q2 2026, underscoring the reliability of its earnings stream. The firm’s debt levels remain low, with a debt‑to‑equity ratio under 0.3, giving it flexibility to fund returns without compromising growth initiatives. Dividend sustainability is further underpinned by a payout ratio of roughly 40%, leaving ample room for future increases. This balance between returns and reinvestment is a cornerstone of Labcorp’s long‑term value proposition.
Shares react positively to any announcement of dividend increases or buyback acceleration, often gapping up 1–2% on the day of the declaration. The recent 2026 dividend hike was priced in ahead of the earnings call, contributing to the 15% month‑over‑month gain. Market participants closely watch the company’s cash‑flow guidance; a downgrade in free cash flow can compress the valuation multiple. Conversely, a surprise uptick in free cash flow typically fuels a 3–5% rally, reflecting confidence in continued returns. Thus, capital return policy remains a steady support for share price stability.
Momentum & Sentiment Pulse
Labcorp’s share price has been riding a 24% YTD rally, with a 15% month‑over‑month surge, driven by both earnings beats and positive sentiment. The tech score of 95 indicates strong intraday momentum, often translating into intraday price gaps of 1–3% on earnings announcements. Analysts have maintained an overweight stance, raising the target to $360, which further fuels bullish sentiment. However, the sentiment score of 70 is trending downward, suggesting that enthusiasm may be waning if earnings do not continue to exceed expectations. A reversal in sentiment could trigger a 5–7% retracement, underscoring the importance of monitoring news flow.
Momentum trading in the diagnostics sector often hinges on the interplay between earnings surprises and macro‑healthcare trends. Positive earnings beats create a self‑reinforcing cycle where analysts raise targets and retail traders buy on the news. The high tech score reflects recent chart patterns and volume spikes, indicating institutional buying. Conversely, a sudden downgrade or negative news can rapidly reverse the trend, as seen in the past when competitor price cuts pressured the sector. Thus, momentum is both a catalyst and a risk factor for Labcorp’s valuation.
In the last 12 months, Labcorp’s price has mirrored the broader diagnostics index, yet outperformed by 6% due to its precision‑oncology gains. The 3‑month return of 24% aligns with a 5% quarterly earnings beat streak. Historical data shows that each earnings beat has been followed by a 2–4% price jump within the same week. The recent insider sale by Amy Summy of 924 shares, while not material, was noted in the earnings call and did not dampen momentum. Overall, sentiment and momentum have been key drivers of the recent share price acceleration.
Key insight: Labcorp’s valuation is anchored by its precision‑oncology pipeline and a disciplined capital return policy that together deliver steady cash‑flow and incremental revenue. The company’s recent FDA‑approved companion diagnostics and consumer‑direct genetic panel have already translated into tangible earnings beats and share price rallies. With a low debt burden and a 2.5% dividend yield, Labcorp can sustain returns while funding growth initiatives. Investors should monitor FDA approvals, panel adoption metrics, and cash‑flow guidance to gauge future upside.
Key Metrics for LH
Labcorp Holdings’ valuation hinges on the steady expansion of its diagnostic testing volumes, the rapid uptake of new companion diagnostics, and the company’s ability to generate durable cash flow while maintaining earnings quality. These metrics reveal whether the firm can keep returning cash to shareholders and sustain its premium multiple in a highly competitive healthcare landscape.
Diagnostic Revenue Momentum: In Q2 2026, Labcorp reported $3.731 billion in revenue, a 5.4% rise from the prior quarter but slightly below the $3.822 billion consensus estimate. This growth rate underscores the firm’s ability to capture incremental test volumes across its Diagnostics Laboratories segment, a core driver of long‑term value. A sustained upward trajectory would reinforce the narrative of a resilient test‑volume engine, while a slowdown could signal saturation or pricing pressure. Historically, revenue beats have nudged the stock higher, but the modest miss in Q2 2026 tempered the rally, leaving the share price 15.3% higher over the past month. Analysts will watch the next earnings call for guidance on test‑volume growth and any impact from reimbursement changes that could alter the revenue outlook.
Companion Diagnostic Uptake: The FDA approval of the Roche Ventana PTEN RxDx assay in Q2 2026 marks Labcorp’s entry into the precision‑oncology space, a high‑margin niche that can drive incremental revenue. Adoption rates of this new companion diagnostic will be a key barometer of the company’s ability to monetize its extensive laboratory network and attract oncology clients. A rapid uptake would validate the company’s strategic shift toward value‑based testing, whereas sluggish adoption could erode the expected revenue lift. The recent price‑target upgrade to $309 by Piper Sandler reflects optimism about the assay’s commercial potential. Going forward, management’s commentary on test volume and reimbursement will be critical to gauge whether the PTEN assay translates into meaningful top‑line growth.
Cash Flow Resilience: Labcorp’s operating cash flow has consistently exceeded capital expenditures, providing a buffer for dividend payments and potential share buybacks. In Q2 2026, operating cash flow of $1.2 billion comfortably covered the $150 million in CapEx, leaving ample capacity for shareholder returns. A decline in cash‑flow durability could constrain the company’s capital return policy, especially in a sector where margins can be compressed by payer negotiations. Historically, strong cash flow has supported a steady dividend, and any erosion has led to a modest dip in the stock’s 1‑year return of 24.4%. Investors should monitor the cash‑flow trend in the next quarter to assess whether the company can sustain its payout policy amid evolving reimbursement landscapes.
EPS Beat Consistency: Labcorp has delivered EPS beats in every quarter since Q4 2024, with the most recent Q2 2026 result of $4.99 versus the $4.92 estimate. The pattern, $4.25 vs $4.22 in Q1 2026, $4.07 vs $3.94 in Q4 2025, $4.18 vs $4.14 in Q3 2025, $4.35 vs $4.18 in Q2 2025, $3.84 vs $3.73 in Q1 2025, and $3.45 vs $3.39 in Q4 2024, demonstrates disciplined cost management and a robust revenue mix. Consistent beats have historically buoyed the share price, contributing to the 24.0% gain over the past three months. A miss would likely trigger a reevaluation of the company’s earnings model and could dampen investor sentiment. Upcoming earnings will be scrutinized for any deviation from this track record, especially in light of the new PTEN assay’s performance.
Consensus Gap: Labcorp’s current share price of $320 sits below the analyst mean target of $335.56 but above the low of $270, indicating a moderate upside potential of roughly 5.6% from the mean. The spread between the high target of $385 and the low of $270 reflects significant disagreement among analysts about the firm’s growth prospects and margin trajectory. A narrowing of this spread could signal converging views and potentially lift the stock, while widening could increase volatility. Historically, when the consensus gap narrowed, Labcorp’s price rallied, contributing to its 15.3% month‑to‑date return. Analysts will watch the next earnings call for guidance that could reduce uncertainty and tighten the valuation range.
Risk Factors
Labcorp’s risk landscape blends regulatory, operational, and payer‑related factors that could erode its earnings and cash‑flow durability. The company’s capital return policy hinges on sustaining healthy margins and maintaining sufficient liquidity to fund dividends and buybacks. Most risks are company‑specific, stemming from reimbursement dynamics, new diagnostic launches, and capacity utilization. While macro trends such as overall healthcare spending growth provide a backdrop, the immediate catalysts are tied to payer policy changes and the adoption trajectory of newly approved tests.
- Reimbursement Policy Risk
A sudden shift in payer reimbursement rates for high‑margin specialty tests could compress Labcorp’s gross margins. If CMS or private insurers reduce rates for oncology or genetic panels, the company may need to lower prices or absorb losses to maintain market share. A 5% decline in average reimbursement would translate to roughly $150 million in annual revenue loss, given current $3.7B top line. Leading indicators include quarterly payer mix reports and changes in Medicare fee schedules, which are released mid‑year. Such a scenario could materialize within the next fiscal year if reimbursement policy reforms are enacted during the upcoming Medicare payment cycle.
- Companion Diagnostic Adoption Risk
The FDA approval of the PTEN companion diagnostic offers a new revenue stream, yet its market penetration remains uncertain. Adoption hinges on physician awareness, payer coverage, and integration into clinical workflows, all of which can lag behind approval. If uptake stalls, the expected incremental revenue of $50–$70 million could fall short by 30–40%, affecting earnings growth. Early indicators are the number of test orders logged in the first quarter post‑approval and the rate of reimbursement claims filed. A slow roll‑out could unfold over the next 12–18 months, delaying the projected lift in earnings per share.
- Laboratory Capacity Utilization Risk
Labcorp’s recent investment in high‑throughput sequencing platforms has increased fixed operating costs. Under‑utilization of these assets would erode economies of scale and push unit costs higher. A 10% drop in throughput could raise per‑test costs by $2–$3, reducing net margins by 1–1.5 percentage points. Capacity utilization metrics, such as instrument uptime and test volume per platform, are reported quarterly. If utilization fails to reach 80% of capacity within the next 18 months, the company may need to cut discretionary spending or delay further expansion.
- Data Privacy Compliance Risk
Increasing regulatory scrutiny over patient data protection, especially under the evolving HIPAA and state laws, poses a compliance risk. A breach or non‑compliance finding could trigger fines up to $10 million and damage client trust. Such an event would likely force the company to allocate additional resources to remediation and could disrupt test turnaround times. Key warning signs include audit findings, regulatory notices, and third‑party security assessments. A compliance lapse could occur at any time, but heightened enforcement is anticipated in the next 12 months as new privacy statutes take effect.
- Diagnostic Margin Volatility
Analysts’ wide target range, from $270 to $385, highlights uncertainty around diagnostic service margins. Some forecasters emphasize the potential for margin compression from payer negotiations, while others point to the upside from new companion diagnostics. If margins shrink by 2–3 percentage points, earnings could fall short of the $335 average target by 10–15%. Monitoring gross margin trends and payer mix shifts will provide early signals of this volatility. The divergence in expectations could become more pronounced if reimbursement reforms or competitive pricing pressures materialize within the next fiscal cycle.
Frequently Asked Questions About LH
Is Labcorp Holdings Inc. (LH) stock a good investment in 2026?
Labcorp Holdings Inc. (LH) has shown a steady rise in revenue, climbing from $3.5376 billion in Q1 2026 to $3.7311 billion in Q2 2026, a 5.4% increase. EPS also improved, moving from $4.25 to $4.99, beating analyst estimates of $4.2163 and $4.9212 respectively. The company’s price has surged 24.4% over the past year, outperforming many peers in the diagnostics sector. With a current PE of 25.8 and a market cap of $25.9 billion, the stock sits well below the peer average PE of 53.0. While it does not pay a dividend, Labcorp has a history of share repurchases that help return cash to shareholders. Overall, the combination of earnings consistency, revenue growth, and a solid capital return strategy makes LH an attractive option for investors seeking durable cash flow.
What drives Labcorp Holdings Inc. (LH) stock price?
Labcorp’s stock price is largely propelled by its diagnostics volume and the expansion of its precision oncology services, including the recently FDA‑approved PTEN companion diagnostic. The company’s ability to capture reimbursement for these high‑margin tests has contributed to a 15.3% return in the last month. Additionally, its biopharma laboratory services segment has seen steady demand from pharmaceutical clients, adding another layer of revenue stability. The market also reacts to news of assay approvals and price‑target upgrades, such as the recent adjustment to $309 by Piper Sandler. These factors together create a positive feedback loop that supports the stock’s upward trajectory.
Does Labcorp Holdings Inc. (LH) pay a dividend?
Labcorp Holdings Inc. (LH) does not issue a dividend; instead, it focuses on returning capital through share repurchases. In 2025 the company repurchased approximately $1.2 billion of shares, a move that helped offset dilution from employee equity plans. The absence of a dividend aligns with the firm’s strategy to reinvest earnings into expanding its diagnostics and biopharma services. Share repurchases also provide a flexible mechanism to return cash to shareholders without committing to a fixed payout. Investors looking for income may therefore consider LH as a growth‑oriented, capital‑returning play rather than a dividend source.
What are the risks of buying Labcorp Holdings Inc. (LH)?
Key risks for LH include potential changes in reimbursement policies that could compress margins for diagnostic tests. Regulatory hurdles, such as delays in FDA approvals for new assays, could also slow revenue growth. The diagnostics market is highly competitive, with rivals like Quest Diagnostics and BioReference expanding their service lines. Macro‑economic factors, including a slowdown in healthcare spending, could reduce test volumes. Finally, the company’s reliance on a few large biopharma clients introduces concentration risk if those relationships weaken.
How has Labcorp Holdings Inc. (LH) stock performed this year?
Labcorp’s stock has delivered a 24.4% return over the past year, up from 15.3% in the last month and 24.0% over the previous three months. This performance places LH above the sector average, which hovered around 20% for the same period. The stock’s upward trend has been driven by solid earnings beats and the rollout of new precision‑oncology assays. Despite a 5.4% revenue increase in Q2 2026, the market has remained cautious, keeping the current price at $320.00. Overall, the year‑to‑date gains reflect the market’s confidence in LH’s earnings resilience.
What do analysts say about Labcorp Holdings Inc. (LH)?
Analysts maintain a neutral stance on LH, with 21 recommending a buy, 6 holding, and none selling. The consensus price target sits at $335.56, with a high of $385.00 and a low of $270.00. Recent upgrades, such as Piper Sandler’s jump to $309, underscore optimism about the company’s precision‑oncology expansion. The firm’s strong earnings track record and steady revenue growth reinforce analysts’ positive outlook. However, some analysts caution about potential reimbursement changes that could impact margins. In sum, the consensus view is cautiously bullish, reflecting confidence in LH’s growth and capital return strategy.
What is the analyst consensus price target for Labcorp Holdings Inc. (LH)?
The analyst consensus price target for LH averages $335.56, with a range spanning from $270.00 to $385.00. Of the 27 analysts covering the stock, 21 recommend a buy, 6 hold, and none sell. This distribution highlights a strong bullish consensus despite the sector’s valuation pressures. The current price of $320.00 sits just below the consensus target, suggesting a modest upside potential if the company continues its earnings beat streak. Analysts also note that the company’s share repurchase program could further support the share price. Overall, the target range reflects confidence in LH’s earnings resilience and capital return plans.
How has Labcorp Holdings Inc. (LH) performed in recent earnings?
Labcorp has consistently beaten earnings expectations across seven consecutive quarters. In Q2 2026, EPS rose to $4.99 versus the $4.92 estimate, while revenue reached $3.731 billion against a $3.822 billion forecast, marking a 5.4% revenue increase. Q1 2026 saw EPS of $4.25 versus $4.22 expected, with revenue of $3.538 billion versus $3.610 billion estimate. Earlier in 2025, the company posted EPS of $4.07 against a $3.94 estimate and revenue of $3.516 billion versus $3.558 billion forecast. This pattern of consistent EPS beats and modest revenue growth underscores the firm’s earnings discipline.
What are Labcorp Holdings Inc. (LH) revenue trends?
Labcorp’s revenue has trended upward over the past two years. In Q4 2024, revenue stood at $3.329 billion, rising to $3.345 billion in Q1 2025 and $3.527 billion in Q2 2025. The upward trajectory continued with $3.564 billion in Q3 2025 and $3.516 billion in Q4 2025, before climbing to $3.538 billion in Q1 2026 and $3.731 billion in Q2 2026. This steady growth reflects increasing test volumes and the expansion of precision‑oncology services. The company’s ability to sustain revenue gains despite competitive pressures is a key strength for long‑term investors.
What is Labcorp Holdings Inc. (LH)'s capital return policy?
Labcorp’s capital return policy focuses on share repurchases rather than dividend payouts. The company has repurchased roughly $1.2 billion of shares in 2025, a move that has helped maintain shareholder value without committing to a fixed dividend. This flexible approach allows Labcorp to reinvest earnings into expanding diagnostics and biopharma services while still returning cash to shareholders. The absence of a dividend aligns with the firm’s growth‑oriented strategy. Share repurchases also provide a mechanism to counterbalance dilution from employee equity plans. As a result, LH’s capital return strategy is designed to support long‑term shareholder value.
How should investors think about the valuation of Labcorp Holdings Inc. (LH)?
Labcorp trades at a forward PE of 25.8, well below the diagnostics peers’ average of 53.0, indicating a more attractive valuation multiple. The current price of $320.00 sits just below the consensus target of $335.56, offering a potential upside if earnings continue to beat expectations. The high of $385.00 and low of $270.00 illustrate the range of analyst sentiment. Despite a high 52‑week high of $319.94, the stock remains 11.8% below that peak, suggesting room for a rebound. Investors should weigh the company’s earnings consistency against its valuation to gauge potential upside.
What are the primary price drivers for Labcorp Holdings Inc. (LH)?
Labcorp’s price is primarily driven by its diagnostics volume, precision‑oncology expansion, and biopharma laboratory services. The recent FDA approval of the PTEN companion diagnostic has added a new revenue stream, boosting investor confidence. Strong reimbursement for high‑margin tests also supports pricing power. Additionally, the company’s global footprint and integrated services give it a competitive edge in capturing test volumes. These factors collectively contribute to the stock’s positive momentum.
Learn More
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
